Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSEIDON trial of tamoxifen with or without GDC-0032 in endocrine-resistant HR-positive metastatic breast cancer
NL-OMON55501Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of taselisib / pictilisib and tamoxifen in breast cancer (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Recommended phase II dose and Progression-free survival. Started Jan 2015; status: active, not recruiting.
02
Drugs
taselisib / pictilisibtamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON55501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55501.